-
This indeed makes it much more difficult to pin down and see which physicians are using which drugs, but from their own internal sales information each drug company will have sales from drug stores, so the overall business from a pre set territory can be derived, so perhaps a new curve in Pharma marketing...
-
The general public as a whole are lost when it comes to the complete understanding of how a clinical trial can benefit their potential treatment plans. There is enough information on the web by all means, but how do you get the information to an individual and explain both the potential benefits...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-07-2008
Filed under:
Filed under: Medically Related, Technology, drugs, healthcare, EHR, Pharma, PHR, clinical trials, Software integration, Point of Care, Personalized Clinical Trials
-
I will once more mention a potential change of paradigms here with educating the public. Each patient who took the drug is unique. Do we have any information on other drugs they were taking at the same time? Groups will continue to advise against the use until the full facts are known...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-31-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, PHR, FDA, Marketing, paradigms, personal heatlh records
-
The company has formed a “strategic partnership” with inVentiv Health , who does a lot of outsourcing for big Pharma, earlier this year, so perhaps some the sales and marketing slated for sales will be moving in this direction. Merck is not the only company investigating and pursuing this direction...
-
Reports of four experimental drugs held up at the FDA emerged in the first two days of this week. “ There’s almost certainly a bit of coincidence at work here, but it also seems to be one more sign of the tough safety climate at the agency these days .” Below are the 4 drugs. No doubt the...
-
I wonder if all the name brand companies will one day have nothing but generics? (grin). There’s always this interesting topic too, biosimilars. “Because biosimilars aren't exact duplicates of the original drugs, they don't violate the original drug's patent , enabling legal distribution...
-
Whistle blowers today seem to be playing a role in the move towards transparency in more ways than one, not to mention the bounty that could be there if a case goes to court and wrongdoing is found to be the case. BD A New Jersey arbitrator ruled that a former Amgen sales rep can proceed with a...
-
The UK continues to say “no” to cancer drugs due to price. If you stop and look at the prices for cancer drugs, something along the line here is going to need to balance soon. It is great and wonderful to have the R and D and great breakthroughs that are occurring almost daily, but what good does...
-
I think this article somewhat speaks for itself and why reporting is important and this is probably not the last story we will hear on this. If government had wanted to track this, a data base reporting system could have been set up with applicable laws a long time ago requiring payments to be...
-
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
-
Whistle blower case where Pharma Sales representative created an investigation and settlement. Whistle blowers can and do receive portions of settlements, and in this case there was $46 million. The uses marketed by Cephalon were not approved by the FDA. Doctors can prescribe...
-
What the top R and D managers from 4 big Pharma companies were talking about, yes they have a bit more of a cushion than Wall Street, but the failure rates and dollars invested don’t seem to be coming together too well either, from the Wall Street Health Blog. When you add it up, just these 4 were...
-
This is probably a good move to speed this process up since many pharmaceutical companies have and are looking at moving more trials to India. More information can be read here about the changing face of Pharma in reference to research and development. One more area to think about too is the use...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-19-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Cancer, clinical trials, Congress, DNA Testing, National Cancer Institute, Justice Department
-
One more survey, do we really need to spend this money, I think we have a pretty good idea here that it is not many. My personal opinion here would be to spend the money and enable and educate folks on how this can be done, rather than to see how many can’t, it’s an obvious. If the money...
-
The battle of the “heartbreak of psoriasis”, my trial is better than yours! BD A new Johnson & Johnson drug trial has put Amgen on the defensive. According to the 903-patient study, J&J's experimental drug ustekinumab (Stelara) proved more effective at treating psoriasis than...